Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

M. Ayers, W. F. Symmans, J. Stec, A. I. Damokosh, E. Clark, K. Hess, M. Lecocke, J. Metivier, D. Booser, N. Ibrahim, V. Valero, M. Royce, B. Arun, G. Whitman, J. Ross, N. Sneige, G. N. Hortobagyi, L. Pusztai, Kathy Miller

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)211-213
Number of pages3
JournalWomen's Oncology Review
Volume4
Issue number3
DOIs
StatePublished - Sep 2004

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology
  • Cancer Research

Cite this

Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., Valero, V., Royce, M., Arun, B., Whitman, G., Ross, J., Sneige, N., Hortobagyi, G. N., Pusztai, L., & Miller, K. (2004). Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review, 4(3), 211-213. https://doi.org/10.1080/14733400412331310974